223 related articles for article (PubMed ID: 8957161)
1. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
Perry CM; Balfour JA
Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
[TBL] [Abstract][Full Text] [Related]
2. Didanosine: an updated review of its use in HIV infection.
Perry CM; Noble S
Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.
Perry CM; Faulds D
Drugs; 1997 Apr; 53(4):657-80. PubMed ID: 9098665
[TBL] [Abstract][Full Text] [Related]
4. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Adkins JC; Peters DH; Faulds D
Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
[TBL] [Abstract][Full Text] [Related]
5. Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.
Moreno S; Hernández B; Dronda F
Drugs; 2007; 67(10):1441-62. PubMed ID: 17600392
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
Bhana N; Ormrod D; Perry CM; Figgitt DP
Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
8. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
9. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
Faulds D; Brogden RN
Drugs; 1992 Jul; 44(1):94-116. PubMed ID: 1379914
[TBL] [Abstract][Full Text] [Related]
10. The role of didanosine in the management of HIV-1 infection.
Gazzard BG; Moyle GJ
Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
[TBL] [Abstract][Full Text] [Related]
11. Update on didanosine.
Cooper DA
J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):15-25. PubMed ID: 12942665
[TBL] [Abstract][Full Text] [Related]
12. Stavudine: an update of its use in the treatment of HIV infection.
Hurst M; Noble S
Drugs; 1999 Nov; 58(5):919-49. PubMed ID: 10595868
[TBL] [Abstract][Full Text] [Related]
13. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
Collier AC; Coombs RW; Fischl MA; Skolnik PR; Northfelt D; Boutin P; Hooper CJ; Kaplan LD; Volberding PA; Davis LG; Henrard DR; Weller S; Corey L
Ann Intern Med; 1993 Oct; 119(8):786-93. PubMed ID: 8379600
[TBL] [Abstract][Full Text] [Related]
16. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
[TBL] [Abstract][Full Text] [Related]
17. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.
Lea AP; Faulds D
Drugs; 1996 May; 51(5):846-64. PubMed ID: 8861550
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
19. Didanosine once daily: potential for expanded use.
Pollard RB
AIDS; 2000 Nov; 14(16):2421-8. PubMed ID: 11101051
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
